TFF Pharmaceuticals, Inc.

And welcome to the TFF Pharmaceuticals Inc. Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star and then zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Corey Davis. Thank you, and you may proceed.

Thank you, operator.

Hello, everyone, and welcome to TFF Pharmaceutical's third quarter financial and business results conference call. With me on the line today is Glenn Mattis, president and CEO of TFF, Kirk Coleman, chief financial officer, Dr. Dale Christensen, TFF's head of preclinical and clinical development, Dr. Bill Williams of the University of Texas at Austin, and Chris Cano, TFF's Chief Operating Officer. A press release announcing our third quarter results is available on the recently updated TFF Pharmaceuticals website, and we hope you all have an opportunity to visit the site soon. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings released in this teleconference both include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in the disclaimer and in our filings with the U.S. Securities and Exchange Commission, including the risk factor section of our 2021 annual report on Form 10-K filed with the SEC. And now it's my pleasure to turn the call over to Mr. Glenn Mattis. Go ahead, Glenn.